1,2-Dichloroethane → HCID 178429228、化合物
反応式
[F:1][C:2]1[CH:7]=[C:6]([C:8]([F:11])([F:10])[F:9])[CH:5]=[CH:4][C:3]=1[CH:12]1[CH2:17][C:16](=[O:18])[NH:15][C:14]([CH3:19])=[C:13]1[C:20]([OH:22])=O.[NH2:23][C:24]1[CH:25]=[C:26]2[C:30](=[CH:31][CH:32]=1)[NH:29][N:28]=[C:27]2[Br:33].C(Cl)CCl.CCN(CC)CC>CN(C=O)C.CCOC(C)=O.Cl>[Br:33][C:27]1[C:26]2[C:30](=[CH:31][CH:32]=[C:24]([NH:23][C:20]([C:13]3[CH:12]([C:3]4[CH:4]=[CH:5][C:6]([C:8]([F:11])([F:10])[F:9])=[CH:7][C:2]=4[F:1])[CH2:17][C:16](=[O:18])[NH:15][C:14]=3[CH3:19])=[O:22])[CH:25]=2)[NH:29][N:28]=1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 3
実験手順
The product of Example 21, Step 2 (200 mg, 0.63 mmol, 1.00 equiv), 5-amino-3-bromoindazole (134 mg, 0.63 mmol, 1.0 equiv), and EDC (145 mg, 0.757 mmol, 1.20 equiv) were suspended in 1.75 mL DMF. Et3N (0.106 mL, 0.757 mmol, 1.2 equiv) was added and the solution was stirred at room temperature for 18 hrs. The reaction mixture was diluted with EtOAc and 1N HCl. The phases were separated, and the organic phase was washed twice with 1N HCl, once with satd. NaHCO3, and once with satd. NaCl. The organic phase was dried over Na2SO4, filtered, and concentrated en vacuo. The residue was purified by flash chromatography (20-100% EtOAc in Hexanes) and further purified by reverse-phase HPLC (10-80% CH3CN/H2O—NH4OH to pH 10 over 17 minutes, retention time 12.59 min) to provide 65 mg (20%) of the title compound as a white solid. MS (ES+) m/e 511 [M+H]+
後処理
- customThe phases were separated
- washthe organic phase was washed twice with 1N HCl, once with satd
- dry with materialThe organic phase was dried over Na2SO4
- filtrationfiltered
- concentrationconcentrated en vacuo
- customThe residue was purified by flash chromatography (20-100% EtOAc in Hexanes)
- customfurther purified by reverse-phase HPLC (10-80% CH3CN/H2O—NH4OH to pH 10 over 17 minutes, retention time 12.59 min)
出典と根拠
- ORDレコード
- ord-935e756d862e4a668359b95d80b91848
- 出典データセット
- uspto-grants-2009_09
- 特許番号
- US07592357B2
反応ノート
読み込み中…